A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)

A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)

Vaccination of the population is one of the most effective countermeasures in responding to the pandemic caused by novel coronavirus infection. Therefore, scientists all over the world have been working to develop effective and safe vaccines. We have developed a synthetic peptide vaccine, EpiVacCoro...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: A. B. Ryzhikov, Е. А. Ryzhikov, M. P. Bogryantseva, S. V. Usova, E. D. Danilenko, E. A. Nechaeva, O. V. Pyankov, O. G. Pyankova, A. S. Gudymo, S. A. Bodnev, G. S. Onkhonova, E. S. Sleptsova, V. I. Kuzubov, N. N. Ryndyuk, Z. I. Ginko, V. N. Petrov, A. A. Moiseeva, P. Yu. Torzhkova, S. A. Pyankov, T. V. Tregubchak, D. V. Antonec, E. V. Gavrilova, R. A. Maksyutov
Formato: article
Lenguaje:RU
Publicado: Sankt-Peterburg : NIIÈM imeni Pastera 2021
Materias:
epivaccorona
peptide vaccine
clinical trials
covid-19
coronavirus
Infectious and parasitic diseases
RC109-216
Acceso en línea:https://doaj.org/article/7df779e259364aabaefcf269dea25ef1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares